Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Discovery Could Lead to Personalized Medical Therapies for Emerging Food Alergy Disorder

By Cincinnati Children's Hospital | May 4, 2018

Scientists at Cincinnati Children’s Hospital Medical Center have uncovered three distinct subtypes of eosinophilic esophagitis (EoE), an emerging food allergic disease. The discovery provides a framework for developing precision medicines to treat this often-debilitating disorder.

The researchers found that each of the three groups, or endotypes (EoEe1, EoEe2, and EoEe3), was associated with different clinical features and molecular pathways.

“Our goal is to provide the type of deep disease understanding and therapeutic decision-making that is now becoming routine in the cancer field,” says Marc Rothenberg, MD, PhD director of Allergy and Immunology at Cincinnati Children’s and senior author of the study. “We applied deep molecular profiling of biopsy tissues from patients undergoing endoscopy to evaluate the presence of EoE.

We found that molecular profiling provided an advantage compared with classical microscopic analysis, the traditional approach to looking at biopsy specimens. These findings provide a potential framework for developing distinct predictive medicine and future therapeutic strategies for specific EoE subpopulations.”

The study, conducted at research institutions throughout the United States, is published online in The Lancet Gastroenterology & Hepatology.

The scientists studied biopsies of 185 children and adults at 10 sites associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). After analyzing various structural and molecular features, they identified endotypes that were consistent across children and adults and were independent of the number of eosinophils in each sample. The three identified endotypes ranged from mild to severe.

Eosinophils are normal cellular components of the blood, but when the body produces too many eosinophils they can cause a variety of eosinophilic disorders, such as EoE. These are disorders involving chronic inflammation and resulting in tissue damage, often in the gastrointestinal system, including the esophagus.

“We have identified genes that are altered within each of the EoE endotypes, establishing insight into distinct disease mechanisms and allowing us to consider personalized treatment approaches,” says Rothenberg. “This is an important stride forward for the allergy and gastroenterology fields. With emerging new therapies for allergic diseases, including a new class of anti-eosinophil drugs, as well as anti-inflammatory biological agents that block specific components of allergic inflammation, this is good news for patients, as this brings the field one step closer to personalized and precision therapy.”

SOURCE: Cincinnati Children’s Hospital


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE